In recent times, Halberd Corporation (OTC:HALB) has emerged as one of the more interesting companies in the biotech space owing to its stellar work with regards to the development of a range of products. On Thursday, the company came into focus after it emerged that its patented LDN+ drug had achieved a major milestone following its entry into the Safety Protocol Trial stage as per the provisions of the CRADA contract for military active duty and veterans.
The patented drug from the company had been developed as a combination of low-dose Naltrexone and Cyclobenzaprime. The product had been the centerpiece of the CRADA (Cooperative Research and Development Agreement) contract that the company had executed with the Tampa, Florida-based Exalted Warrior Foundation along with three other companies. The six-week safety study conducted by the company would involve current active duty as well as retired military volunteers. The study would commence right after the Institutional Review Board (IRB) approval is granted.
William Hartman, the Chief Executive Officer of Halberd, spoke about the latest developments as well. He noted that it was critical that Halberd intellectual property was being deployed in order to tackle the issue of PTSD and depression leading to suicide ideation among the members of the military. The effort from the company as part of a particularly novel CRADA could lead to a considerable reduction in depression, anxiety, and addiction problems.
Over the past four months, the four-company approach has evolved following extensive discussions among the key players. It was also noted that the company’s LDN+ drug also combined drugs that had already been approved by the United States Food and Drug Administration. The drugs had, in fact, been used both individually and collectively by patients over the course of the past few years. It could be a good time to keep an eye on the Halberd stock today.
